Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | ATF4 | P18848 | 9/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21819725 | 0.84 | ATF4 (0.52) | HRH4ATF4NPC1RAB9ASTS | |
| SCHEMBL21882067 | 0.82 | ATF4 (0.59) | HRH4ATF4NPC1RAB9AL3MBTL1 | |
| SCHEMBL29436915 | 0.82 | ATF4 (0.59) | HRH4ATF4NPC1RAB9AL3MBTL1 | |
| SCHEMBL22777318 | 0.82 | KDM4E (0.58) | HRH4NPC1RAB9ASTSMEN1 | |
| SCHEMBL29527235 | 0.82 | KDM4E (0.58) | HRH4NPC1RAB9ASTSMEN1 | |
| SCHEMBL29082741 | 0.82 | KMT2A (0.55) | HRH4NPC1RAB9ASTSKMT2A | |
| SCHEMBL29082665 | 0.81 | RAB9A (0.62) | HRH4NPC1RAB9ASTSL3MBTL1 | |
| SCHEMBL23920292 | 0.81 | ATF4 (0.51) | HRH4ATF4NPC1RAB9AL3MBTL1 | |
| SCHEMBL21819310 | 0.81 | KMT2A (0.54) | HRH4ATF4STSMEN1KMT2A | |
| SCHEMBL3450134 | 0.79 | NAMPT (0.51) | HRH4NPC1RAB9ASTSMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220071966-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2022-03-10 | — | — | US | disclosed |
| US-11166942-B2 | Inhibitors of integrated stress response pathway | Praxis Biotech LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-11166942-B2 | Inhibitors of integrated stress response pathway | Praxis Biotech LLC (US) | 2021-11-09 | — | — | US | disclosed |
| CN-112912082-A | Integrated stress pathway inhibitors | 普拉西斯生物技术有限责任公司 | 2021-06-04 | — | — | CN | disclosed |
| EP-3801522-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2020-04-02 | — | — | US | disclosed |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | ATF4, DDIT3, ATF1 | HRH4 1989/4885ATF4 1/4885NPC1 2384/4885 |
| US-20220071966-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | HRH4 1989/4885ATF4 1/4885NPC1 2384/4885 |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | HRH4 1989/4885ATF4 1/4885NPC1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.